# US 7,745,110 B2 · Adipogenic adenoviruses as a biomarker for disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,110 B2
- Document ID: US7745110B2
- Status: Granted
- Kind: B2
- Application number: 12/257,937
- Filed: 2008-10-24
- Published: 2009-04-02
- Granted: 2010-06-29
- Earliest claimed: 2005-12-27
- Assignees: Obetech, LLC
- Inventors: Richard L Atkinson
- Web page: https://patentgrep.com/patent/US7745110B2

## CPC

- A61K 39/235: Adenoviridae
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/38: of the suprarenal hormones
- A61P 5/48: of the pancreatic hormones
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/701: {Specific hybridization probes}
- G01N 33/575: for cancer
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2710/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G01N 2333/075: Adenoviridae
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to the relationship between infection with an adipogenic adenovirus, such as adenovirus-36, and obesity-related disease. In particular, this invention relates to assaying a subject to determine the adipogenic adenovirus infection status and then determining the subject's predisposition to developing an obesity-related disease based on the adipogenic adenovirus infection status.

## Claims

### Claim 1

A method for determining if a subject is predisposed to developing adipogenic adenovirus type 36-related diabetes, said method comprising the steps of:
obtaining a sample from the subject;
assaying the sample to determine whether the subject is infected with an adipogenic adenovirus type 36; and
determining whether the subject is predisposed to developing diabetes, based on the presence or absence of an adipogenic adenovirus type 36 in the sample, wherein a subject having an adipogenic adenovirus type 36 has a higher pre-disposition for developing diabetes relative to a subject not infected with an adipogenic adenovirus type 36.

### Claim 2 (depends on 1)

The method of claim 1, wherein said step of assaying the sample comprises the steps of:
screening the sample for the presence of antibodies specific to the adipogenic adenovirus type 36 in the sample; and
determining the presence of antibodies specific to the adipogenic adenovirus type 36 in the sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is an non-human animal.

### Claim 5 (depends on 2)

The method of claim 2, wherein the antibodies in said determining step are specific to one or more peptide encoded by the nucleic acid sequences selected from the group consisting of SEQ ID NO.:5, SEQ ID NO.:6, and SEQ ID NO.:7.

### Claim 6 (depends on 2)

The method of claim 2, wherein said screening step is performed by using an immunoanalytical technique.

### Claim 7 (depends on 6)

The method of claim 6, wherein said immunoanalytical technique is one or more techniques selected from the group consisting of serum neutralization assay and enzyme immunoassay.

### Claim 8 (depends on 7)

The method of claim 7, wherein said enzyme immunoassay is selected from the group consisting of ELISA, RIA, IRMA, IEMA, and immunocytochemical assay.

### Claim 9 (depends on 1)

The method of claim 1, wherein the sample is selected from the group consisting of a biological sample, body fluid, a tissue sample, an organ sample, feces, blood, saliva, and any combination thereof.

### Claim 10 (depends on 2)

The method of claim 2, wherein the presence of antibodies specific to the adipogenic adenovirus type 36 in the sample is indicative of a subject being predisposed to developing an obesity-related disease due to adipogenic adenovirus type 36.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject infected with the adipogenic adenovirus type 36 has increased production of lipogenic enzymes in comparison to a subject not infected with the adipogenic adenovirus type 36.

### Claim 12 (depends on 11)

The method of claim 11, wherein lipogenic enzymes are one or more enzymes selected from the group consisting of FAS, glycerol-3-phosphodehydrogenase, lipoprotein lipase, SCD1, CPT 1, and L-type pyruvate kinase.

### Claim 13 (depends on 1)

The method of claim 1, wherein said step of assaying the sample comprises the steps of:
screening the sample for the presence of nucleic acid specific to the adipogenic adenovirus type 36 in the sample; and
determining the presence of nucleic acid specific to the adipogenic adenovirus type 36 in the sample.

### Claim 14 (depends on 13)

The method of claim 13, wherein said step of screening is performed by using a nucleic acid hybridization technique.

### Claim 15 (depends on 14)

The method of claim 14, wherein said nucleic acid hybridization technique is selected from the group consisting of direct DNA sequencing, RNA sequencing, RNase protection assays, PCR, RT-PCR, real time PCR, Si nuclease protection assay, nucleic acid affinity purification, and nucleic acid hybridization.

### Claim 16 (depends on 13)

The method of claim 13, wherein the nucleic acid is DNA selected from the group consisting of cDNA, ssDNA, dsDNA, and genomic DNA.

### Claim 17 (depends on 13)

The method of claim 13, wherein the nucleic acid is RNA selected from the group consisting of mRNA, dsRNA, and ssRNA.

### Claim 18 (depends on 13)

The method of claim 13, wherein the presence of nucleic acid specific to the adipogenic adenovirus type 36 in the sample is indicative of a subject being predisposed to developing an obesity-related disease due to adipogenic adenovirus type 36.